is a biotechnology company focused on developing innovative therapeutics to address unmet medical needs in severe autoimmune and inflammatory diseases. The company's research emphasizes harnessing the immune system to create targeted treatments for conditions such as autoimmune disorders and organ transplant rejection. With a commitment to advancing precision medicine, Equillium aims to improve patient outcomes through its pipeline of novel candidates, which are designed to modulate immune responses and provide more effective solutions for patients suffering from debilitating conditions.
Shares of Westport Fuel Systems Inc. (NASDAQWPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
